
Norstella appoints Kris Joshi as CEO to drive next phase of growth
Ella Day | July 10, 2025 | Appointment | Business Services, Consultancy | CEO, Corporate, HealthTech, Norstella
Pharma intelligence solutions provider, Norstella, has appointed health-tech leader, Kris Joshi, as its new chief executive officer (CEO) with former CEO Mike Gallup stepping into the role of executive chairman.
Joshi is a health-tech executive with over 25 years of experience in healthcare data and technology, product management and business development. He joins Norstella from Optum, where he led the company’s $3bn Software, Network and Data business. His career spans leadership roles at Change Healthcare, Oracle, IBM and McKinsey & Company. He advocates for an AI-first approach to enterprise transformation.
“We have the opportunity to significantly accelerate innovation in the life sciences industry and improve patient access to therapies by connecting insights across the value chain,” said Joshi.
As CEO, Joshi will lead Norstella’s portfolio of pharma intelligence brands – including Citeline, Evaluate, MMIT, Panalgo and The Dedham Group – and its integrated data platform, NorstellaLinQ.
Outgoing CEO Gallup welcomed Joshi’s appointment, stating: “Kris brings sharp insight and a deep understanding of data to the table. Most importantly, he believes in this mission and the company that we’ve built.”
Norstella, formed through the merger of several leading pharma data and consultancy providers, supports the development of life-saving therapies.
Ella Day
10/7/25

This article featured in: August 2025 – The Pharmafile Brief
Related Content

Digital platform for hypertension management launches in Europe
Newel Health, a European healthtech company specialising in digital medical devices, has announced that Amicomed, …

CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

FibroGen rocked by unexpected death of CEO Thomas B Neff
In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, …






